Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity |
| |
Authors: | Qian Weizhu Wang Ling Li Bohua Wang Hao Hou Sheng Hong Xueyu Zhang Dapeng Guo Yajun |
| |
Institution: | a International Joint Cancer Institute, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People’s Republic of China b Shanghai Center for Cell Engineering and Antibody, Shanghai 201203, People’s Republic of China |
| |
Abstract: | Despite the widespread clinical use of CD34 antibodies for the purification of human hematopoietic stem/progenitor cells, all the current anti-human CD34 monoclonal antibodies (mAbs) are murine, which have the potential to elicit human antimouse antibody (HAMA) immune response. In the present study, we developed three new mouse anti-human CD34 mAbs which, respectively, belonged to class I, class II and class III CD34 epitope antibodies. In an attempt to reduce the immunogenicity of these three murine mAbs, their chimeric antibodies, which consisted of mouse antibody variable regions fused genetically to human antibody constant regions, were constructed and characterized. The anti-CD34 chimeric antibodies were shown to possess affinity and specificity similar to that of their respective parental murine antibodies. Due to the potentially better safety profiles, these chimeric antibodies might become alternatives to mouse anti-CD34 antibodies routinely used for clinical application. |
| |
Keywords: | CD34 Monoclonal antibody Immunogenicity Chimeric antibody Hematopoietic stem cells |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|